According to InvestingPro analysis, Phreesia appears undervalued based on its Fair Value estimate, with analysts setting price targets between $23 and $34. The company is scheduled to report earnings in just 4 days, which could be a significant catalyst for the stock.Get deeper insights into insider trading patterns and more with InvestingPro, featuring exclusive ProTips and comprehensive analysis of 1,400+ stocks. In other recent news, Phreesia, a healthcare software company, has been the center of attention among several financial firms following its strong Q2 results. The company reported a 19% year-over-year increase in revenue, totaling $102.1 million. The adjusted EBITDA rose to $6.5 million, marking an $18 million improvement from the previous year. DA Davidson reaffirmed its Buy rating for Phreesia, anticipating strong EBITDA guidance for FY26.